AMRI announced today that it has expanded into the protein market, with an initial focus on protein expression and purification. The global revenue of the total proteomics market is anticipated to grow at a compound annual growth rate of about 4.1% to about $9.2 billion by 2018.
AMRI’s current and ongoing activities – as part of its New York State Public-Private Partnership in Buffalo, N.Y. – encompass the production of purified recombinant proteins as reagents and tools for biological assays and sterile, pyrogen-free materials for proof-of-concept, non-human in vivo studies. Current production capabilities range from a scale of 1 to 100 milligrams. The protein expression systems and methods of focus are E. coli, mammalian and baculovirus.
“As a company with a deep history of discovery innovation, we continue to explore scientific solutions that provide our customers with enhanced flexibility and access to state-of-the-art science and technologies,” said Michael A. Luther, Ph.D., MBA, Senior Vice President of Discovery and Development at AMRI. “We are very excited to be able to offer these expanded biology services as we continue to work with our customers, partners, CNSE, and the State of New York, to provide relevant drug discovery services, cutting-edge platforms and expertise to academia and the global Bio-Pharmaceutical industry from early discovery to candidate selection and beyond.” “Under Governor Andrew Cuomo’s Buffalo Billion Initiative, we look forward to working with AMRI to provide these vital new services at the Buffalo Medical Innovation and Commercialization (BMIC) Hub to support pharmaceutical development, technology optimization, and related research and development opportunities,” said Michael Liehr, Executive Vice President of Innovation and Technology and Vice President for Research of the SUNY CNSE/SUNYIT institution, a lead partner in the BMIC Hub. “The expansion to protein R&D will further leverage scientific knowledge and expertise to produce industry-changing results for stakeholders at every level.”
As part of its aim to provide customers with high-value services in the area of biology and pharmacology, AMRI unveiled an IND-enabling support services platform in March 2014. This platform of services is aimed at supporting the successful initiation and completion of customer IND programs. As part of this offering, AMRI now provides in vitro DMPK studies related to drug-drug interactions and metabolism, which are routinely included in IND submissions.